1-4 of 4
Aishling M. Rada
Close
Sort by
Journal Articles

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Clinical Trials & Observations
Owen A. O’Connor, Lorenzo Falchi, Jennifer K. Lue, Enrica Marchi, Cristina Kinahan, Ahmed Sawas, Changchun Deng, Francesca Montanari, Jennifer E. Amengual, Hye A. Kim, Aishling M. Rada, Karen Khan, Alice T. Jacob, Michelle Malanga, Mark M. Francescone, Renu Nandakumar, Craig R. Soderquist, David C. Park, Govind Bhagat, Bin Cheng, Alberto Risueño, Daniel Menezes, Andrei R. Shustov, Lubomir Sokol, Luigi Scotto
Journal: Blood
Blood (2019) 134 (17): 1395–1405.
https://doi.org/10.1182/blood.2019001285
Published: 2019
Includes: Supplemental data
Journal Articles

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Ahmed Sawas, MD, Hager Elgedawe, George Vlad, PhD, Mikel Lipschitz, M.S., Pei-Hsuan Chen, PhD, Scott J Rodig, MD, Jennifer Kimberly Lue, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Maher Abdul Hay, MD, Karen Khan, BSN, Laine E. Atkins, RN, Aishling M. Rada, RN, Larisa Geskin, MD, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2908.
https://doi.org/10.1182/blood-2018-99-115269
Published: 2018
Journal Articles

Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)

Lorenzo Falchi, MD, Jennifer Kimberly Lue, MD, Francesca Montanari, MD, Enrica Marchi, MD, PhD, Jennifer E Amengual, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Karen Khan, BSN, Hyea Kim, NP-BC, Laine E. Atkins, RN, Aishling M. Rada, RN, Cremers Serge, PhD PharmD, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1002.
https://doi.org/10.1182/blood-2018-99-116605
Published: 2018
Journal Articles

A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)

Lorenzo Falchi, MD, Jennifer Kimberly Lue, MD, Jennifer E Amengual, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Enrica Marchi, MD, PhD, Emily Lichtenstein, RN, Karen Khan, BSN, Hyea Kim, NP-BC, Laine E. Atkins, RN, Aishling M. Rada, RN, Celeste Rojas, Cremers Serge, PhD PharmD, Owen A. O'Connor, MD, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1515.
https://doi.org/10.1182/blood.V130.Suppl_1.1515.1515
Published: 2017